New pain pill SBS-147 enters first human safety trial

NCT ID NCT07335913

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests the safety of an experimental pain drug called SBS-147 in 80 healthy adults. Some participants get the drug, others a placebo. The study has two parts: a single dose group and a group that takes the drug daily for a week. Researchers will monitor side effects and how the body processes the drug. This is a first step to see if SBS-147 is safe enough for future pain studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SBS-147 (experimental drug)

What this could lead to

If safe and well-tolerated, this could lead to further studies testing SBS-147 as a new treatment for acute pain.

What could go wrong

This is a very early Phase 1 trial in healthy people, not patients with pain. It only checks safety and how the drug is processed, not whether it actually relieves pain. Side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AltaSciences, Inc

    RECRUITING

    Cypress, California, 90630, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••